Sachetta LLC Lowers Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Sachetta LLC trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 45.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 108 shares of the pharmaceutical company’s stock after selling 90 shares during the quarter. Sachetta LLC’s holdings in Vertex Pharmaceuticals were worth $43,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Northwest Investment Counselors LLC purchased a new position in Vertex Pharmaceuticals in the third quarter worth $25,000. Dunhill Financial LLC boosted its holdings in shares of Vertex Pharmaceuticals by 70.6% in the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 24 shares during the last quarter. Highline Wealth Partners LLC bought a new position in Vertex Pharmaceuticals during the third quarter valued at about $27,000. Legacy Investment Solutions LLC purchased a new stake in Vertex Pharmaceuticals during the third quarter worth about $33,000. Finally, Truvestments Capital LLC bought a new stake in Vertex Pharmaceuticals in the third quarter worth about $35,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on VRTX shares. Needham & Company LLC restated a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Friday, December 20th. Morgan Stanley increased their price target on Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Barclays lowered their price objective on Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating on the stock in a research note on Friday, December 20th. HC Wainwright cut their target price on shares of Vertex Pharmaceuticals from $600.00 to $535.00 and set a “buy” rating for the company in a research report on Friday, December 20th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating on the stock in a research report on Monday, December 23rd. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $494.84.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ:VRTX opened at $439.62 on Friday. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. The stock has a market cap of $113.22 billion, a PE ratio of -220.91, a PEG ratio of 2.20 and a beta of 0.40. The company’s fifty day moving average is $435.36 and its 200 day moving average is $464.66. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.77. The company had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. Vertex Pharmaceuticals’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the business posted $3.67 EPS. Research analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.